Fuchs Endothelial Corneal Dystrophy Market

The Fuchs endothelial corneal dystrophy market has been comprehensively analyzed in IMARC's new report titled "Fuchs Endothelial Corneal Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fuchs endothelial corneal dystrophy (FECD) is a progressive eye disorder affecting the cornea, the transparent front part of the eye. Characterized by the gradual deterioration of endothelial cells that line the inner surface of the cornea, FECD is often an inherited condition, though sporadic cases can also occur. Symptoms typically manifest in middle-aged to elderly patients, with blurred vision upon waking being a common early sign. As the disease advances, individuals suffering from the ailment may experience pain, sensitivity to light, and visual impairment, ultimately leading to corneal swelling and clouding. Diagnosis of FECD involves a comprehensive eye examination, including measurements of corneal thickness and assessment of endothelial cell density. Additionally, specular microscopy and advanced imaging techniques may be performed to evaluate the severity of the disease.

The escalating incidence of genetic anomaly, which predominantly affects the corneal endothelium, leading to the gradual degeneration of corneal cells and subsequent vision impairment, is primarily driving the Fuchs endothelial corneal dystrophy market. In addition to this, the inflating utilization of advanced medications, including hypertonic saline solutions, corticosteroids, and in some cases, surgical procedures like Descemet's stripping endothelial keratoplasty (DSEK) or Descemet's membrane endothelial keratoplasty (DMEK), is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies that are gaining traction as complementary measures to alleviate symptoms and enhance the quality of life for individuals suffering from FECD, is bolstering the market growth. Apart from this, the rising usage of  innovative treatment modalities, such as the utilization of endothelial keratoplasty and descemetorhexis without endothelial keratoplasty is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cutting-edge approaches, including the exploration of gene therapy, which involves the introduction of functional genetic material to rectify the mutated or malfunctioning genes associated with the disease, is expected to drive the Fuchs endothelial corneal dystrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Fuchs endothelial corneal dystrophy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Fuchs endothelial corneal dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Fuchs endothelial corneal dystrophy market in any manner.

Key Highlights:

• In the United States, around 4% of adults over the age of 40 suffer from late-onset FECD.
• People over the age of 40 and women are more likely to acquire FECD.
• FECD affects women two to four times more than males.
• The female to male ratio in FECD has been found to be 2.5:1 to 3:1.
• FECD is a frequent indication for corneal transplantation, accounting for approximately 20% of all penetrating keratoplasties.

Drugs:

STN1010904 is a sirolimus-based eye drop created by Santen Pharmaceutical Co. Ltd. and ActualEyes, Inc. to treat Fuchs endothelial corneal dystrophy (FECD). STN1010904 is a mTOR inhibitor that slows the course of FECD by inhibiting the apoptosis of corneal endothelial cells.

Netarsudil is an ophthalmic solution created by Alcon to treat corneal edema caused by FECD. Netarsudil is a rho kinase inhibitor that increases the flow of aqueous humor through the trabecular meshwork, lowering intraocular pressure.

TTHX1114 is an experimentally developed variant of the naturally occurring chemical Fibroblast Growth Factor-1 (FGF1), which promotes cell proliferation and migration while shielding cells from stress and injury. Trefoil is currently undertaking clinical trials for TTHX1114 as an intracameral injection into the eye for patients susceptible to corneal edema owing to endothelial dysfunction, including FECD.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Fuchs endothelial corneal dystrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Fuchs endothelial corneal dystrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current Fuchs endothelial corneal dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the Fuchs endothelial corneal dystrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Fuchs endothelial corneal dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Fuchs endothelial corneal dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Fuchs endothelial corneal dystrophy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Fuchs endothelial corneal dystrophy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Fuchs endothelial corneal dystrophy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Fuchs endothelial corneal dystrophy across the seven major markets?
• What is the size of the Fuchs endothelial corneal dystrophy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Fuchs endothelial corneal dystrophy?
• What will be the growth rate of patients across the seven major markets?
   

Fuchs Endothelial Corneal Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Fuchs endothelial corneal dystrophy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Fuchs endothelial corneal dystrophy market?
• What are the key regulatory events related to the Fuchs endothelial corneal dystrophy market?
• What is the structure of clinical trial landscape by status related to the Fuchs endothelial corneal dystrophy market?
• What is the structure of clinical trial landscape by phase related to the Fuchs endothelial corneal dystrophy market?
• What is the structure of clinical trial landscape by route of administration related to the Fuchs endothelial corneal dystrophy market?